Abstract:e15064 Background: The oral fluoropyrimidine X has improved efficacy, safety, and convenience vs. 5-FU/LV in MCRC [Van Cutsem et al. Br J Cancer 2004] and early-stage colon cancer [Twelves et al. NEJM 2005]. A recent study showed that I + X q2w is active and well tolerated [Garcia-Alfonso et al. ESMO 2006]. The humanized monoclonal antibody A targets VEGF and limits tumor angiogenesis. The addition of A to 5-FU/LV/I (IFL regimen) improves survival significantly in patients (pts) with MCRC [Hurwitz et al. NEJM 2004]. Replacing 5-FU/LV with X in this combination is a logical step forward. Here we report data from an open-label phase II trial of XIA in MCRC. METHODS Pts with untreated, histologically confirmed MCRC received I 175mg/m2 i.v. d1, X 1,000 mg/m2 orally bid d2-8, and A 5 mg/m2 d1. Treatment was repeated q2w x 12 cycles in the absence of progressive disease (PD) or unacceptable toxicity. Pts without PD after 12 cycles of XIA continued on the same dose of A + X 1,500 mg/m2 bid d2-8, q2w. The primary endpoint was progression-free survival (PFS); secondary endpoints were overall response rate (ORR, RECIST), overall survival (OS), safety, and quality of life. RESULTS 57 pts have been enrolled. Baseline characteristics: M/F 44%/56%; median age 52 years (range 30-70); disease stage at initial diagnosis II/III/IV 16%/9%/75%; no. of metastatic sites 1/>1 47%/53%; most common metastatic site liver. Pts received a median 12 cycles (range 1-12) of XIA. All 57 pts are evaluable for safety and 56 for efficacy. ORR is 46% (3 CR, 13 PR); 5 pts (22%) have stable disease and 35 have PD. Median PFS and OS are 14.9 months (range 1.7-39.2) and 18.3 months (range 2.9-39.2), respectively. Grade 3 adverse events occurring in more than 1 pt are diarrhea (9%), hypertension (9%), hand-foot syndrome (7%), ileus (4%), and hypertriglyceridemia (4%); there is one report of grade 4 leucopenia. CONCLUSIONS The XIA combination appears to be highly active and well tolerated as first-line treatment for MCRC; further studies of XIA are warranted. [Table: see text].

Method of testing antibiotic sensitivity of spirochaetes, using antibiotic discs.

Improved contractile force generation of tissue-engineered skeletal muscle constructs by IGF-I and Bcl-2 gene transfer with electrical pulse stimulation

Creatine kinase estimation in pure fetal blood samples for the prenatal diagnosis of duchenne muscular dystrophy

Pre-resonance stimulated Raman scattering spectroscopy and imaging of membrane potential using near-infrared rhodopsins

A Preliminary Study of Comparison of Preventive and Therapeutic Effect of Green and White Tea Against Rifampicin-Induced Chronic Hepatotoxicity in Rats

Crystal structure of heliorhodopsin

Hijacking of internal calcium dynamics by intracellularly residing viral rhodopsins

Electronic Preresonance Stimulated Raman Scattering Imaging of Red-Shifted Proteorhodopsins: Toward Quantitation of the Membrane Potential.

Cervical cancers diagnosed after negative results on cervical cytology.

Functional expression of the eukaryotic proton pump rhodopsin OmR2 in Escherichia coli and its photochemical characterization

Heliorhodopsin-mediated light-modulation of ABC transporter

Thermal and spectroscopic characterization of a proton pumping rhodopsin from an extreme thermophile

Involvement of Deg5 protease in wounding-related disposal of PsbF apoprotein.

Expanding the family of genetically encoded voltage indicators with a candidate Heliorhodopsin exhibiting near-infrared fluorescence

Unique hydrogen-bonding network in a viral channelrhodopsin

His-75 in proteorhodopsin, a novel component in light-driven proton translocation by primary pumps

Mechanism of Inward Proton Transport in an Antarctic Microbial Rhodopsin

The roles of an extended N-terminal region and ETD motif in a pump-like cation channelrhodopsin discovered in a lake microbiome

Retinal Chromophore Environment in an Inward Light-Driven Proton Pump Studied by Solid-state NMR and Hydrogen-Bond Network Analysis

Updated phase II study results of capecitabine (X) + irinotecan (I) + bevacizumab (A) as first-line therapy for metastatic colorectal cancer (MCRC).

Ion transport activity and optogenetics capability of light-driven Na+-pump KR2